Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Presentation symbols : Tgtx save search
TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
Published: 2024-04-15 (Crawled : 12:00) - globenewswire.com
TGTX | $14.255 1.1% 280K
|
Health Technology
|
| O: -3.94%
H: 3.0%
C: -0.57%
briumvi neurology presentation sclerosis for meeting therapeutics
TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
Published: 2024-03-01 (Crawled : 12:30) - globenewswire.com
TGTX | $14.255 1.1% 280K
|
Health Technology
|
| O: 1.86%
H: 4.79%
C: 2.39%
briumvi presentation sclerosis treatment research therapeutics
TG Therapeutics Announces Presentation of Data for BRIUMVI at the 2023 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
Published: 2023-10-12 (Crawled : 15:30) - globenewswire.com
TGTX | $14.255 1.1% 280K
|
Health Technology
|
| O: -1.65%
H: 0.56%
C: -3.21%
briumvi presentation sclerosis treatment research meeting therapeutics
TG Therapeutics Announces Presentation of Data for BRIUMVI at the 2023 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
Published: 2023-10-11 (Crawled : 15:00) - globenewswire.com
TGTX | $14.255 1.1% 280K
|
Health Technology
|
| O: 2.97%
H: 1.7%
C: -4.46%
briumvi presentation sclerosis treatment research meeting therapeutics
TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the 2023 Consortium of Multiple Sclerosis Centers Annual Meeting
Published: 2023-06-02 (Crawled : 13:20) - globenewswire.com
TGTX | $14.255 1.1% 280K
|
Health Technology
|
| O: 0.67%
H: 0.54%
C: -3.77%
briumvi presentation sclerosis trials meeting therapeutics
TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 75th Annual Meeting
Published: 2023-04-25 (Crawled : 14:20) - biospace.com/
TGTX | $14.255 1.1% 280K
|
Health Technology
|
| O: 0.09%
H: 8.17%
C: -1.19%
briumvi presentation sclerosis trials meeting therapeutics
TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab-xiiy) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
Published: 2023-02-24 (Crawled : 13:00) - biospace.com/
TGTX | $14.255 1.1% 280K
|
Health Technology
|
| O: -2.49%
H: 1.2%
C: -2.12%
treatment trials research therapeutics presentation sclerosis multiple sclerosis
TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the 2022 European Committee for Treatment and Research in Multiple Sclerosis
Published: 2022-10-26 (Crawled : 12:00) - globenewswire.com
TGTX | $14.255 1.1% 280K
|
Health Technology
|
| O: -0.93%
H: 11.07%
C: 3.75%
treatment trials research therapeutics presentation sclerosis multiple sclerosis
TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the 8Th Congress of the European Academy of Neurology
Published: 2022-06-27 (Crawled : 12:00) - biospace.com/
TGTX | $14.255 1.1% 280K
|
Health Technology
|
| O: -1.36%
H: 2.53%
C: 0.0%
trials therapeutics presentation sclerosis phase 3
TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the 2022 Consortium of Multiple Sclerosis Centers Annual Meeting
Published: 2022-06-03 (Crawled : 12:00) - globenewswire.com
TGTX | $14.255 1.1% 280K
|
Health Technology
|
| O: 5.63%
H: 11.62%
C: 6.54%
trials therapeutics presentation sclerosis phase 3 multiple sclerosis
TG Therapeutics to Participate in the H.C. Wainwright Global Investment Conference Presentation available for on demand download beginning Tuesday May 24, 2022 at 7:00 AM ET
Published: 2022-05-20 (Crawled : 12:00) - biospace.com/
TGTX | $14.255 1.1% 280K
|
Health Technology
|
| O: -4.42%
H: 4.45%
C: -7.71%
conference therapeutics presentation
TG Therapeutics Announces Oral Presentation of Data from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the American Academy of Neurology Annual Meeting
Published: 2022-04-06 (Crawled : 12:00) - globenewswire.com
TGTX | $14.255 1.1% 280K
|
Health Technology
|
| O: -2.1%
H: 3.71%
C: 2.34%
trials therapeutics presentation sclerosis phase 3
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the American Academy of Neurology Annual Meeting
Published: 2022-03-04 (Crawled : 13:00) - biospace.com/
TGTX | $14.255 1.1% 280K
|
Health Technology
|
| O: -11.07%
H: 0.0%
C: 0.0%
america multiple sclerosis als trials trial therapeutics presentation sclerosis phase 3
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
Published: 2022-02-25 (Crawled : 13:00) - globenewswire.com
TGTX | $14.255 1.1% 280K
|
Health Technology
|
| O: 10.03%
H: 0.0%
C: 0.0%
america multiple sclerosis treatment als trials research trial therapeutics presentation sclerosis phase 3
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
Published: 2022-02-15 (Crawled : 13:30) - biospace.com/
TGTX | $14.255 1.1% 280K
|
Health Technology
|
| O: 2.51%
H: 8.21%
C: 6.84%
america multiple sclerosis treatment als trials research trial therapeutics presentation sclerosis phase 3
TG Therapeutics Announces Data Presentations at the 63rd American Society of Hematology (ASH) Annual Meeting
Published: 2021-12-13 (Crawled : 13:30) - biospace.com/
TGTX | $14.255 1.1% 280K
|
Health Technology
|
| O: 0.5%
H: 0.0%
C: 0.0%
ema therapeutics presentation
TG Therapeutics Recaps Schedule of Data Presentations at the Upcoming 63rd American Society of Hematology (ASH) Annual Meeting
Published: 2021-12-10 (Crawled : 12:30) - globenewswire.com
TGTX | $14.255 1.1% 280K
|
Health Technology
|
| O: -5.62%
H: 0.0%
C: 0.0%
ema therapeutics presentation
TG Therapeutics Highlights Data Selected for Presentation at the 63rd American Society of Hematology (ASH) Annual Meeting
Published: 2021-11-04 (Crawled : 14:00) - globenewswire.com
TGTX | $14.255 1.1% 280K
|
Health Technology
|
| O: -2.37%
H: 8.96%
C: 8.47%
presentation ema
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
Published: 2021-09-29 (Crawled : 12:00) - globenewswire.com
TGTX | $14.255 1.1% 280K
|
Health Technology
|
| O: 0.7%
H: 2.16%
C: 0.9%
presentation multiple sclerosis treatment europe trials sclerosis phase 3 research trial
TG Therapeutics Announces Combination Data Presentations at the XIX International Workshop on Chronic Lymphocytic Leukemia (iwCLL)
Published: 2021-09-20 (Crawled : 12:00) - biospace.com/
TGTX | $14.255 1.1% 280K
|
Health Technology
|
| O: -2.05%
H: 3.68%
C: 2.06%
presentation leukemia
Gainers vs Losers
| 83% | 17% |
Top 10 Gainers
MTTR | News M | $4.625 165.81% 5.5M
|
AGBA | $2.615 109.2% 14M
|
Finance
EDBL | News | $7.37 96.01% 650K
|
PALI | $7.64 54.97% 14M
|
Manufacturing
OPRT | News | $3.19 41.78% 3M
|
Finance
PEGY | $0.0629 37.34% 110M
|
Manufacturing
MLEC | $1.87 33.57% 1.6M
|
n/a
ATGL | $3.66 27.97% 150K
|
VNRX | $0.759 26.5% 390K
|
Health Technology
SMFL | $5.35 22.99% 11M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.